TABLE 3

Clinical phases for β-lactam/β-lactamase inhibitor combinations

β-Lactam/β-lactamase inhibitor combinationClinical phaseExpected activityPotential indicationsaReference(s)
Ceftaroline-avibactam2Active against Gram-negative ESKAPE and CDC pathogensBacterial infections154
Aztreonam-avibactam2Active against Gram-negative ESKAPE and CDC pathogensComplicated intra-abdominal infections155
Imipenem-cilastatin-relebactam (MK-7655)3Active against Gram-negative ESKAPE and CDC pathogenscUTIs, cIAIs, hospital-acquired and ventilator-associated bacterial pneumonia156
Meropenem-vaborbactam (RPX-7009) (also known as carbavance)New drug application submittedActive against Gram-negative ESKAPE and CDC pathogenscUTIs, hospital-acquired and ventilator-associated bacterial pneumonia, febrile neutropenia, bacteremia, infections caused by carbapenem-resistant Enterobacteriaceae157, 158
Biapenem-vaborbactam (RPX-7009)1Active against Gram-negative ESKAPE and CDC pathogensAnaerobic bacterial infection159
ETX2514SULActive against Gram-negative ESKAPE pathogensInfection caused by A. baumannii160
Cefepime-zidebactam1Active against Gram-negative ESKAPE pathogens, possible activity against CDC pathogenscUTIs, hospital-acquired and ventilator-associated bacterial pneumonia161
  • a cUTIs, complicated urinary tract infections; cIAIs, complicated intra-abdominal infections.